Barclays PLC Voyager Therapeutics, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 104,462 shares of VYGR stock, worth $603,790. This represents 0.0% of its overall portfolio holdings.

Number of Shares

104,462

Previous 104,462 -0.0%

Holding current value

$603,790

Previous $612,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$5.77 - $9.27 $215,786 - $346,679	37,398 Added 55.76%	104,462 $612,000
Q2 2024 Aug 14, 2024	BUY	$7.42 - $10.54 $59,745 - $84,868	8,052 Added 13.64%	67,064 $530,000
Q1 2024 May 15, 2024	SELL	$7.15 - $10.84 $51,401 - $77,928	-7,189 Reduced 10.86%	59,012 $548,000
Q4 2023 Feb 15, 2024	BUY	$6.28 - $8.81 $300,761 - $421,928	47,892 Added 261.58%	66,201 $559,000
Q3 2023 Nov 07, 2023	BUY	$7.55 - $11.25 $90,373 - $134,662	11,970 Added 188.83%	18,309 $141,000
Q2 2023 Aug 03, 2023	SELL	$6.94 - $13.99 $201,933 - $407,067	-29,097 Reduced 82.11%	6,339 $72,000
Q1 2023 May 04, 2023	BUY	$6.0 - $10.78 $119,850 - $215,330	19,975 Added 129.2%	35,436 $273,000
Q4 2022 Feb 13, 2023	BUY	$4.94 - $6.61 $67,001 - $89,651	13,563 Added 714.59%	15,461 $94,000
Q3 2022 Nov 03, 2022	BUY	$5.57 - $7.47 $10,571 - $14,178	1,898 New	1,898 $11,000
Q4 2021 Feb 14, 2022	SELL	$2.47 - $5.55 $8,603 - $19,330	-3,483 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$2.63 - $4.12 $10,417 - $16,319	-3,961 Reduced 53.21%	3,483 $9,000
Q2 2021 Aug 13, 2021	SELL	$3.94 - $5.44 $56,389 - $77,857	-14,312 Reduced 65.78%	7,444 $31,000
Q1 2021 May 13, 2021	BUY	$4.61 - $9.04 $60,953 - $119,526	13,222 Added 154.93%	21,756 $103,000
Q4 2020 Feb 11, 2021	SELL	$7.15 - $12.28 $24,116 - $41,420	-3,373 Reduced 28.33%	8,534 $60,000
Q3 2020 Nov 12, 2020	SELL	$10.01 - $13.75 $51,000 - $70,056	-5,095 Reduced 29.97%	11,907 $127,000
Q2 2020 Aug 12, 2020	BUY	$8.05 - $14.21 $64,271 - $113,452	7,984 Added 88.53%	17,002 $215,000
Q1 2020 May 13, 2020	SELL	$6.8 - $14.66 $112,315 - $242,139	-16,517 Reduced 64.68%	9,018 $82,000
Q4 2019 Feb 10, 2020	SELL	$12.82 - $16.85 $51,715 - $67,972	-4,034 Reduced 13.64%	25,535 $356,000
Q3 2019 Nov 14, 2019	SELL	$16.31 - $28.29 $29,814 - $51,714	-1,828 Reduced 5.82%	29,569 $509,000
Q2 2019 Aug 14, 2019	BUY	$19.18 - $27.88 $480,056 - $697,808	25,029 Added 393.04%	31,397 $855,000
Q1 2019 May 15, 2019	BUY	$8.0 - $19.66 $49,336 - $121,243	6,167 Added 3068.16%	6,368 $122,000
Q4 2018 Feb 14, 2019	SELL	$8.59 - $18.05 $155,461 - $326,668	-18,098 Reduced 98.9%	201 $2,000
Q3 2018 Nov 14, 2018	BUY	$17.11 - $21.74 $24,467 - $31,088	1,430 Added 8.48%	18,299 $347,000
Q2 2018 Aug 14, 2018	SELL	$16.76 - $23.92 $263,266 - $375,735	-15,708 Reduced 48.22%	16,869 $330,000
Q1 2018 May 15, 2018	BUY	$16.16 - $31.31 $87,506 - $169,543	5,415 Added 19.94%	32,577 $612,000
Q4 2017 Feb 14, 2018	BUY	$12.26 - $25.88 $153,556 - $324,147	12,525 Added 85.57%	27,162 $451,000
Q3 2017 Nov 14, 2017	BUY	$8.37 - $20.59 $122,511 - $301,375	14,637	14,637 $301,000

Others Institutions Holding VYGR

# of Institutions

130

Shares Held

34.7M

Call Options Held

39.7K

Put Options Held

34.6K

View Full List

About Voyager Therapeutics, Inc.

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $223M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

More about VYGR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account